USPTO Patent Applications - Pharma (A61K)

USPTO Patent Application: Sialic Acid Compositions for Coronavirus Infections

The USPTO has published a patent application (US20260083762A1) detailing compositions comprising sialic acid for inhibiting or treating coronavirus infections, specifically those caused by SARS-CoV-2. The application was filed on August 18, 2025, by inventor Jan Remmereit.

USPTO Patent Application for NAD+ Concentration Support Compositions

The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.

USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment

The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.

USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases

The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.

USPTO Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083763A1) for liquid compositions containing fiber as a prebiotic dietary supplement. The application details formulations designed to maintain or improve gut microbiome health.

USPTO Patent Application: Stable Liquid Bortezomib Formulations

The USPTO has published a patent application (US20260083760A1) for stable liquid bortezomib formulations filed by Riconpharma LLC. The application describes liquid compositions with specific impurity limits for intravenous or subcutaneous use.

USPTO Patent Application: Psychedelics Combined with NMDA Receptor Agonists

The USPTO has published a patent application (US20260083759A1) detailing combinations of psychedelic drugs with NMDA receptor agonists for treating neuropsychiatric and neurologic disorders. The application was filed on August 29, 2023, and is scheduled for publication on March 26, 2026.

USPTO Patent Application for Self-Emulsifying Drug Delivery Systems

The USPTO has published a patent application from Fertin Pharma A/S for a dosage form utilizing self-emulsifying drug delivery systems (SEDDS) for cannabinoids. The application details specific formulations including surfactants with PEG moieties and isolated or synthetic cannabinoids.

USPTO Patent Application for Tyk2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.

USPTO Patent Application: Cannabinoid Delivery Capsules

The USPTO has published a new patent application (US20260083756A1) from Fertin Pharma A/S for capsules designed for peroral cannabinoid delivery. The application details formulations using self-emulsifying drug delivery systems (SEDDS) with specific surfactant and cannabinoid content.

USPTO Patent Application: TYK2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.

Testosterone Composition for Oral Delivery Treats Hypogonadism

The USPTO has published a patent application (US20260083755A1) assigned to NEUROCRINE UK LIMITED for a testosterone-containing pharmaceutical composition adapted for oral delivery. The application details treatment regimens and methods for hormone-related conditions like hypogonadism in human subjects.

USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation

The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.

USPTO Patent Application: Upadacitinib Pharmaceutical Composition

The USPTO has published a new patent application (US20260083732A1) detailing a pharmaceutical composition for upadacitinib. The application, filed on September 6, 2023, describes a formulation involving upadacitinib, a hydrophobic release-controlling polymer, a pH modifier, and other excipients.

Uveal Melanoma Treatment Patent Application

The USPTO has published a patent application (US20260083731A1) detailing methods for treating uveal melanoma using a PKC inhibitor. The application, filed on August 25, 2023, by inventors Matthew Anthony Maurer, Michael Gabriel O'Quigley, and Julie Hambleton, focuses on neoadjuvant and/or adjuvant therapy to reduce metastasis and preserve eye function.

USPTO Patent Application for Metabolic Syndrome Treatment

The USPTO has published a patent application (US20260083753A1) for compositions and methods to treat metabolic syndrome. The application, filed by Kotha Sekharam, details improved compositions with enhanced solubility and bioavailability.

Patent Application: Cancer Treatment Methods and Compositions

The USPTO has published a patent application (US20260083752A1) for methods and compositions for treating cancer. The application, filed by the Regents of the University of Minnesota, involves the combination of p300/CBP modulators with senotherapeutics.

USPTO Patent Application: Allosteric Modulators for CRPC Therapy

The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.

USPTO Patent Application: Dapiprazole for Eye Disorders

The USPTO has published a patent application (US20260083730A1) for a method of treating eye disorders using dapiprazole. The application, filed by Baradaina LLC, details a liquid composition for treating conditions such as presbyopia, glaucoma, or halos and glare.

USPTO Patent Application: Small Molecule Inhibitors of KRAS Proteins for Cancer Treatment

The USPTO has published a patent application (US20260083750A1) detailing small molecule inhibitors of KRAS proteins for cancer treatment. The application describes compounds that can inhibit specific KRAS protein mutants and their potential utility as therapeutic agents for cancer.

USPTO Patent for Anti-CD123 Immunoconjugates Treating AML

The USPTO has published a patent application (US20260083749A1) for anti-CD123 immunoconjugates, such as pivekimab sunirine, for treating acute myeloid leukemia (AML). The patent covers methods of use as monotherapies or in combination with other agents to achieve remission or prepare patients for transplant.

USPTO Patent Application: Compositions for Mitochondrial Health

The USPTO has published a patent application (US20260083747A1) detailing compositions for supporting mitochondrial health using methylthioninium salts combined with other compounds. The application was filed on October 30, 2024, by inventors Darren Lopez and Dan Schmidt.

USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells

The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.

Reduced Dosing Regimens for Glaucoma Treatment Methods

The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.

USPTO Patent Application for Visual Pathway Strengthening Methods

The USPTO has published a new patent application (US20260083744A1) for methods of treating visual impairment by strengthening visual pathways. The application was filed on September 26, 2025, by inventors Ming-Fai Fong and Robert D. Lamprecht.

USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections

The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.

USPTO Publishes Antiseptic Wipes Patent Application

The USPTO published a patent application for antiseptic wipes on March 26, 2026. The application details a cleansing composition including an antiseptic, humectant, emollient, surfactant, and monohydric alcohol, designed for use on a cloth. The invention also covers methods of preparing and packaging the wipes.

USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment

The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.

Patent Application for Cancer Treatment with Azenosertib and HRD Biomarker

The USPTO has published a patent application (US20260083742A1) detailing methods for treating cancer by administering azenosertib to subjects selected based on homologous recombination repair deficiency (HRD). The application was filed on December 1, 2025.

Sotorasib Dosing Regimen Patent Application

The USPTO has received a patent application (US20260083741A1) for a sotorasib dosing regimen. The application, filed by Brett E. Houk and Panli Cardona, details methods for administering sotorasib to patients, particularly those with KRAS G12C-mutated cancer who also require treatment with a BCRP substrate like rosuvastatin.

USPTO Patent Application: Dental Composition Production Method

The USPTO has published a patent application (US20260083644A1) detailing a method for producing dental polymerizable compositions or intermediates with improved storage stability. The method involves specific steps for disposing and operating a composition within a container to achieve high yield and stability.

USPTO Patent Application: Dietary Compositions for Health and Diabetes Treatment

The USPTO has published a patent application (US20260083739A1) for dietary compositions containing minerals and vitamins, intended for various health benefits including diabetes treatment, improved athletic performance, and immune support. The application was filed on December 2, 2025.

USPTO Patent Application: Modified Release Minoxidil for Hair Loss

The USPTO has published a patent application (US20260083738A1) detailing modified release minoxidil oral formulations for treating hair loss. The application, filed by Reid Waldman, describes compositions including minoxidil alone or with other active agents, and methods of treatment. This represents a new patent filing for a potential pharmaceutical product.

USPTO Patent Application: Method for Coloring Dental Ceramic

The USPTO has published a patent application detailing a method for coloring dental ceramic using a solution containing specific metal ions. The application, filed by inventors from Japan, describes a process involving contacting the dental ceramic with a coloring liquid where the difference between standard oxidation-reduction potentials of at least two metal ions is between 0.5 and 4.0.

USPTO Patent Application: Dental Composition with Stable Paste Properties

The USPTO has published a new patent application detailing a dental composition designed for stable paste properties. The invention focuses on a specific filler composition and its surface treatment to improve long-term storage stability for dental materials.

USPTO Patent Application: Modified Release Minoxidil Formulations

The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.

USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder

The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.

USPTO Patent Application for ABHD6 Antagonist Drug

The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.

Collagenase Compositions for Orthodontic Procedures Patent Application

The USPTO has published a patent application detailing compositions comprising collagenase and their uses in orthodontic procedures. The application, filed by inventors from Israel, describes potential uses for recombinant collagenase and modified forms thereof in dental treatments.

USPTO Patent Application: T cell isolation methods

The USPTO has published patent application US20260079159A1 detailing methods for isolating and expanding specific types of T cells (CD127lo/− regulatory T cells) for potential use in treating immune system disorders. The application was filed on September 12, 2025.

USPTO Patent Application: Pyramidal Meditation Structure Device

The USPTO has published a patent application for a pyramidal meditation structure device. The application, filed by Rein Daloul, describes a structure with vertical beams, walls, an entrance, and integrated pipes with crystals intended to impart healing energy during meditation.

USPTO Patent Application: Sjögren's Syndrome Detection and Treatment

The USPTO has published a patent application detailing methods for detecting and treating Sjögren's syndrome using salivary exosomes. The application, filed by inventors from various institutions, outlines novel diagnostic and therapeutic approaches for the autoimmune disease.

USPTO Patent Application: Predicting Disease State by Analyzing cfDNA Fragments

The USPTO has published a patent application (US20260080975A1) filed by Foundation Medicine, Inc. The application describes methods for predicting disease states by analyzing cell-free DNA (cfDNA) fragments. This is a routine publication of a patent application.

USPTO Patent Application: HRD Cancer Classification and Treatment

The USPTO has published a patent application from Foundation Medicine, Inc. detailing systems and methods for classifying and treating homologous repair deficiency (HRD) cancers. The application describes models for identifying HRD-positive tumors and suggests combination therapies, such as FOLFIRINOX, for treatment.